Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 2, 2020

Primary Completion Date

May 21, 2022

Study Completion Date

May 17, 2023

Conditions
Wilson Disease
Interventions
DRUG

Bis-Choline Tetrathiomolybdate

Participants will be initiated at 15 milligrams once daily, then the dose will be increased to 30 milligrams once daily at Week 6.

Trial Locations (12)

1010

Research Site, Grafton

8200

Research Site, Århus N

46026

Research Site, Valencia

48109

Research Site, Ann Arbor

75235

Research Site, Dallas

95817

Research Site, Sacramento

119021

Research Site, Moscow

169608

Research Site, Singapore

194017

Research Site, Saint Petersburg

M5G 2C4

Research Site, Toronto

08036

Research Site, Barcelona

SE5 9RS

Research Site, London

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY